Abstract

Research Article

An update on the approaches of avoidance of propagation of chronic kidney disease resulting in reversal or possible need or avoidance of kidney transplantation - a systematic review

Kulvinder Kochar Kaur*, Gautam Allahbadia and Mandeep Singh

Published: 10 May, 2022 | Volume 6 - Issue 2 | Pages: 040-057

Chronic Kidney Disease (CKD) by definition is a disease characterized by irreversible elimination of renal function, which keeps propagating as corroborated by an estimated glomerular filtration rate (eGFR) of < 60 ml/min/1.73m2, the constant existence of presentation which pointed to Kidney injury (proteinuria, active sediments of urine, histological injury, structural aberrations or prior history with regards to Kidney transplantation) or both that are persistent for greaterthan 3 mths [1].

Read Full Article HTML DOI: 10.29328/journal.jcn.1001089 Cite this Article Read Full Article PDF

References

  1. Kidney Disease ImprovingGlobal Outcomes (KDIGO) CKD Work Group. KDIGO 2012. Clinical Practice Guidelinesfor the evaluation and management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1-150.
  2. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006 Jul;17(7):2034-47. doi: 10.1681/ASN.2005101085. Epub 2006 May 31. PMID: 16738019.
  3. Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nat Rev Nephrol. 2020 May;16(5):269-288. doi: 10.1038/s41581-019-0248-y. Epub 2020 Feb 14. PMID: 32060481.
  4. Stevens LA, Viswanathan G, Weiner DE. Chronic kidney disease and end-stage renal disease in the elderly population: current prevalence, future projections, and clinical significance. Adv Chronic Kidney Dis. 2010 Jul;17(4):293-301. doi: 10.1053/j.ackd.2010.03.010. PMID: 20610356; PMCID: PMC3160131.
  5. Duan J, Wang C, Liu D, Qiao Y, Pan S, Jiang D, Zhao Z, Liang L, Tian F, Yu P, Zhang Y, Zhao H, Liu Z. Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in Chinese rural residents: a cross-sectional survey. Sci Rep. 2019 Jul 18;9(1):10408. doi: 10.1038/s41598-019-46857-7. PMID: 31320683; PMCID: PMC6639314.
  6. Yan MT, Chao CT, Lin SH. Chronic Kidney Disease: Strategies to Retard Progression. Int J Mol Sci. 2021 Sep 18;22(18):10084. doi: 10.3390/ijms221810084. PMID: 34576247; PMCID: PMC8470895.
  7. Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, Toto RD, Wang X, Wright JT Jr, Greene TH. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis. 2012 Apr;59(4):504-12. doi: 10.1053/j.ajkd.2011.12.009. Epub 2012 Jan 26. PMID: 22284441; PMCID: PMC3312980..
  8. Lee DE, Qamar M, Wilke RA. Relative Contribution of Genetic and Environmental Factors in CKD. S D Med. 2021 Jul;74(7):306-309. PMID: 34449991.
  9. Beyer-Westendorf J, Kreutz R, Posch F, Ay C. The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. Int J Cardiol. 2018 Feb 15;253:71-77. doi: 10.1016/j.ijcard.2017.10.110. PMID: 29306476.
  10. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006 Feb;116(2):288-96. doi: 10.1172/JCI27699. PMID: 16453013; PMCID: PMC1359063.
  11. Ca nades–Garre M, Anderson K, Cappa R, Shelly R, Smyth LJ, et al. Genetic susceptibility to Chronic Kidney Disease -some more pieces for the heritabilitypuzzle. Front 2019;10:453.
  12. Djudjaj S, Boor P. Cellular and molecular mechanisms of kidney fibrosis. Mol Aspects Med. 2019 Feb;65:16-36. doi: 10.1016/j.mam.2018.06.002. Epub 2018 Jun 22. PMID: 29909119.
  13. Grande MT, Sánchez-Laorden B, López-Blau C, De Frutos CA, Boutet A, Arévalo M, Rowe RG, Weiss SJ, López-Novoa JM, Nieto MA. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat Med. 2015 Sep;21(9):989-97. doi: 10.1038/nm.3901. Epub 2015 Aug 3. Erratum in: Nat Med. 2016 Feb;22(2):217. PMID: 26236989.
  14. Hajarnis S, Yheskel M, Williams D, Brefort T, Glaudemans B, Debaix H, Baum M, Devuyst O, Patel V. Suppression of microRNA Activity in Kidney Collecting Ducts Induces Partial Loss of Epithelial Phenotype and Renal Fibrosis. J Am Soc Nephrol. 2018 Feb;29(2):518-531. doi: 10.1681/ASN.2017030334. Epub 2017 Oct 11. PMID: 29021386; PMCID: PMC5791084.
  15. Canaud G, Bonventre JV. Cell cycle arrest and the evolution of chronic kidney disease from acute kidney injury. Nephrol Dial Transplant. 2015 Apr;30(4):575-83. doi: 10.1093/ndt/gfu230. Epub 2014 Jul 12. PMID: 25016609; PMCID: PMC4370290.
  16. Lovisa S, LeBleu VS, Tampe B, Sugimoto H, Vadnagara K, Carstens JL, Wu CC, Hagos Y, Burckhardt BC, Pentcheva-Hoang T, Nischal H, Allison JP, Zeisberg M, Kalluri R. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med. 2015 Sep;21(9):998-1009. doi: 10.1038/nm.3902. Epub 2015 Aug 3. PMID: 26236991; PMCID: PMC4587560.
  17. Chung KW, Lee EK, Lee MK, Oh GT, Yu BP, Chung HY. Impairment of PPARαand the Fatty Acid Oxidation Pathway Aggravates Renal Fibrosis during Aging. J Am Soc Nephrol. 2018 Apr;29(4):1223-1237. doi: 10.1681/ASN.2017070802. Epub 2018 Feb 12. PMID: 29440279; PMCID: PMC5875952.
  18. Liu BC, Tang TT, Lv LL, Lan HY. Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int. 2018 Mar;93(3):568-579. doi: 10.1016/j.kint.2017.09.033. Epub 2018 Jan 17. PMID: 29361307.
  19. Song Y, Lv S, Wang F, Liu X, Cheng J, Liu S, Wang X, Chen W, Guan G, Liu G, Peng C. Overexpression of BMP‑7 reverses TGF‑β1‑induced epithelial‑mesenchymal transition by attenuating the Wnt3/β‑catenin and TGF-β1/Smad2/3 signaling pathways in HK‑2 cells. Mol Med Rep. 2020 Feb;21(2):833-841. doi: 10.3892/mmr.2019.10875. Epub 2019 Dec 10. PMID: 31974602; PMCID: PMC6947920.
  20. Tampe B, Tampe D, Nyamsuren G, Klöpper F, Rapp G, Kauffels A, Lorf T, Zeisberg EM, Müller GA, Kalluri R, Hakroush S, Zeisberg M. Pharmacological induction of hypoxia-inducible transcription factor ARNT attenuates chronic kidney failure. J Clin Invest. 2018 Jul 2;128(7):3053-3070. doi: 10.1172/JCI89632. Epub 2018 Jun 11. PMID: 29664738; PMCID: PMC6025987.
  21. Tampe B, Steinle U, Tampe D, Carstens JL, Korsten P, Zeisberg EM, Müller GA, Kalluri R, Zeisberg M. Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression. Kidney Int. 2017 Jan;91(1):157-176. doi: 10.1016/j.kint.2016.07.042. Epub 2016 Sep 28. PMID: 27692563.
  22. Morgado-Pascual JL, Rayego-Mateos S, Tejedor L, Suarez-Alvarez B, Ruiz-Ortega M. Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases. Front Pharmacol. 2019 Nov 8;10:1315. doi: 10.3389/fphar.2019.01315. PMID: 31780938; PMCID: PMC6857099.
  23. Mello MLS. Sodium Valproate-Induced Chromatin Remodeling. Front Cell Dev Biol. 2021 Apr 20;9:645518. doi: 10.3389/fcell.2021.645518. PMID: 33959607; PMCID: PMC8093769.
  24. Kaur KK, Allahbadia GN, Singh M. Potential role of Epigenetic Modulation in prevention or therapy for Diabetic Kidney Disease-still a dream or a reality–A Systematic Review. J Diab Nephro Diab Mgmt. 2021:1:1(1-26).
  25. Heung M, Steffick DE, Zivin K, Gillespie BW, Banerjee T, Hsu CY, Powe NR, Pavkov ME, Williams DE, Saran R, Shahinian VB; Centers for Disease Control and Prevention CKD Surveillance Team. Acute Kidney Injury Recovery Pattern and Subsequent Risk of CKD: An Analysis of Veterans Health Administration Data. Am J Kidney Dis. 2016 May;67(5):742-52. doi: 10.1053/j.ajkd.2015.10.019. Epub 2015 Dec 12. PMID: 26690912; PMCID: PMC6837804.
  26. Liu KD, Yang J, Tan TC, Glidden DV, Zheng S, Pravoverov L, Hsu CY, Go AS. Risk Factors for Recurrent Acute Kidney Injury in a Large Population-Based Cohort. Am J Kidney Dis. 2019 Feb;73(2):163-173. doi: 10.1053/j.ajkd.2018.08.008. Epub 2018 Oct 25. PMID: 30482577; PMCID: PMC6647831.
  27. Amdur RL, Chawla LS, Amodeo S, Kimmel PL, Palant CE. Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. Kidney Int. 2009 Nov;76(10):1089-97. doi: 10.1038/ki.2009.332. Epub 2009 Sep 9. PMID: 19741590.
  28. Kashani K, Kellum JA. Novel biomarkers indicating repair or progression after acute kidney injury. Curr Opin Nephrol Hypertens. 2015 Jan;24(1):21-7. doi: 10.1097/MNH.0000000000000090. PMID: 25415614.
  29. Göcze I, Jauch D, Götz M, Kennedy P, Jung B, Zeman F, Gnewuch C, Graf BM, Gnann W, Banas B, Bein T, Schlitt HJ, Bergler T. Biomarker-guided Intervention to Prevent Acute Kidney Injury After Major Surgery: The Prospective Randomized BigpAK Study. Ann Surg. 2018 Jun;267(6):1013-1020. doi: 10.1097/SLA.0000000000002485. PMID: 28857811.
  30. Little MH, Kairath P. Does Renal Repair Recapitulate Kidney Development? J Am Soc Nephrol. 2017 Jan;28(1):34-46. doi: 10.1681/ASN.2016070748. Epub 2016 Oct 26. PMID: 27798243; PMCID: PMC5198297.
  31. Sato Y, Yanagita M. Immune cells and inflammation in AKI to CKD progression. Am J Physiol Renal Physiol. 2018 Dec 1;315(6):F1501-F1512. doi: 10.1152/ajprenal.00195.2018. Epub 2018 Aug 29. PMID: 30156114.
  32. Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N, Mira JP, Dequin PF, Gergaud S, Weiss N, Legay F, Le Tulzo Y, Conrad M, Robert R, Gonzalez F, Guitton C, Tamion F, Tonnelier JM, Guezennec P, Van Der Linden T, Vieillard-Baron A, Mariotte E, Pradel G, Lesieur O, Ricard JD, Hervé F, du Cheyron D, Guerin C, Mercat A, Teboul JL, Radermacher P; SEPSISPAM Investigators. High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014 Apr 24;370(17):1583-93. doi: 10.1056/NEJMoa1312173. Epub 2014 Mar 18. PMID: 24635770.
  33. Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson S, Xenou M, Clayton T, Yellon DM; ERICCA Trial Investigators. Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. N Engl J Med. 2015 Oct 8;373(15):1408-17. doi: 10.1056/NEJMoa1413534. Epub 2015 Oct 5. PMID: 26436207.
  34. Floege J, Amann K. Primary glomerulonephritides. Lancet. 2016 May 14;387(10032):2036-48. doi: 10.1016/S0140-6736(16)00272-5. Epub 2016 Feb 25. PMID: 26921911.
  35. Friedman DJ, Pollak MR. APOL1and Kidney Disease: From Genetics to Biology. Annu Rev Physiol. 2020 Feb 10;82:323-342. doi: 10.1146/annurev-physiol-021119-034345. Epub 2019 Nov 11. PMID: 31710572.
  36. Turkmen K, Baloglu I. Fabry disease: where are we now? Int Urol Nephrol. 2020 Nov;52(11):2113-2122. doi: 10.1007/s11255-020-02546-3. Epub 2020 Jul 13. PMID: 32661622.
  37. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017 Mar 25;389(10075):1238-1252. doi: 10.1016/S0140-6736(16)32064-5. Epub 2016 Nov 23. PMID: 27887750.
  38. Gnudi L, Coward RJM, Long DA. Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms. Trends Endocrinol Metab. 2016 Nov;27(11):820-830. doi: 10.1016/j.tem.2016.07.002. Epub 2016 Jul 25. PMID: 27470431.
  39. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045. doi: 10.2215/CJN.11491116. Epub 2017 May 18. PMID: 28522654; PMCID: PMC5718284.
  40. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, Chahin J, Méndez ML, Gallego E, Macía M, del Castillo N, Rivero A, Getino MA, García P, Jarque A, García J. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol. 2015 Jan;26(1):220-9. doi: 10.1681/ASN.2014010012. Epub 2014 Jun 26. PMID: 24970885; PMCID: PMC4279740.
  41. Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD. Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials. J Am Heart Assoc. 2019 May 7;8(9):e010827. doi: 10.1161/JAHA.118.010827. PMID: 31020900; PMCID: PMC6512126.
  42. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G; DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005 Mar;45(3):485-93. doi: 10.1053/j.ajkd.2004.11.004. PMID: 15754270.
  43. Sarafidis PA. Thiazolidinediones and diabetic nephropathy: need for a closer examination? J Cardiometab Syndr. 2007 Fall;2(4):297-301. doi: 10.1111/j.1559-4564.2007.07834.x. PMID: 18059215.
  44. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12. PMID: 28605608.
  45. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. PMID: 30990260.
  46. Alicic RZ, Neumiller JJ, Johnson EJ, Dieter B, Tuttle KR. Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes. 2019 Feb;68(2):248-257. doi: 10.2337/dbi18-0007. Erratum in: Diabetes. 2019 May;68(5):1094. PMID: 30665953.
  47. Tejedor Jorge A. Hemodynamic and renal implications of sodium-glucose cotransporter- 2 inhibitors in type 2 diabetes mellitus. Med Clin (Barc). 2016 Nov;147 Suppl 1:35-43. English, Spanish. doi: 10.1016/S0025-7753(17)30624-3. PMID: 28760224.
  48. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28. PMID: 27470878.
  49. Fernandez-Fernandez B, Sarafidis P, Kanbay M, Navarro-González JF, Soler MJ, Górriz JL, Ortiz A. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. Clin Kidney J. 2020 Oct 9;13(5):728-733. doi: 10.1093/ckj/sfaa198. PMID: 33123352; PMCID: PMC7577767.
  50. Costa R, Remigante A, Civello DA, Bernardinelli E, Szabó Z, Morabito R, Marino A, Sarikas A, Patsch W, Paulmichl M, Janáky T, Miseta A, Nagy T, Dossena S. O-GlcNAcylation Suppresses the Ion Current IClswell by Preventing the Binding of the Protein ICln to α-Integrin. Front Cell Dev Biol. 2020 Nov 19;8:607080. doi: 10.3389/fcell.2020.607080. PMID: 33330510; PMCID: PMC7717961.
  51. Okada Y, Numata T, Sato-Numata K, Sabirov RZ, Liu H, Mori SI, Morishima S. Roles of volume-regulatory anion channels, VSOR and Maxi-Cl, in apoptosis, cisplatin resistance, necrosis, ischemic cell death, stroke and myocardial infarction. Curr Top Membr. 2019;83:205-283. doi: 10.1016/bs.ctm.2019.03.001. Epub 2019 Apr 19. PMID: 31196606.
  52. Sugahara S, Kume S, Chin-Kanasaki M, Tomita I, Yasuda-Yamahara M, Yamahara K, Takeda N, Osawa N, Yanagita M, Araki SI, Maegawa H. Protein O-GlcNAcylation Is Essential for the Maintenance of Renal Energy Homeostasis and Function viaLipolysis during Fasting and Diabetes. J Am Soc Nephrol. 2019 Jun;30(6):962-978. doi: 10.1681/ASN.2018090950. Epub 2019 May 1. PMID: 31043434; PMCID: PMC6551777.
  53. Fürst J, Gschwentner M, Ritter M, Bottà G, Jakab M, Mayer M, Garavaglia L, Bazzini C, Rodighiero S, Meyer G, Eichmüller S, Wöll E, Paulmichl M. Molecular and functional aspects of anionic channels activated during regulatory volume decrease in mammalian cells. Pflugers Arch. 2002 May;444(1-2):1-25. doi: 10.1007/s00424-002-0805-1. Epub 2002 Mar 8. PMID: 11976912.
  54. Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. Am J Kidney Dis. 2019 Jul;74(1):120-131. doi: 10.1053/j.ajkd.2018.12.044. Epub 2019 Mar 19. PMID: 30898362.
  55. Kidney Disease Improving Global Outcomes (KDIGO) BP Work Group. KDIGO 2021. Clinical Practice Guidelinesfor the management of blood pressure in Am J Kidney Dis. 2013;62:201-13.
  56. Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, Sanders PW, Textor SC, Weir MR, Townsend RR. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013 Aug;62(2):201-13. doi: 10.1053/j.ajkd.2013.03.018. Epub 2013 May 16. PMID: 23684145; PMCID: PMC3929429.
  57. Hsu CN, Tain YL. Gasotransmitters for the Therapeutic Prevention of Hypertension and Kidney Disease. Int J Mol Sci. 2021 Jul 21;22(15):7808. doi: 10.3390/ijms22157808. PMID: 34360574; PMCID: PMC8345973.
  58. Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4. PMID: 33107592; PMCID: PMC8094274.
  59. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014 Apr 29;(4):CD007004. doi: 10.1002/14651858.CD007004.pub3. Update in: Cochrane Database Syst Rev. 2020 Oct 27;10:CD007004. PMID: 24782282.
  60. Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021 Jan 7;42(2):152-161. doi: 10.1093/eurheartj/ehaa736. PMID: 33099609; PMCID: PMC7813624.
  61. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. PMID: 33264825.
  62. Rico-Mesa JS, White A, Ahmadian-Tehrani A, Anderson AS. Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone. Curr Cardiol Rep. 2020 Sep 10;22(11):140. doi: 10.1007/s11886-020-01399-7. PMID: 32910349.
  63. Kim JS, Hwang HS. Vascular Calcification in Chronic Kidney Disease: Distinct Features of Pathogenesis and Clinical Implication. Korean Circ J. 2021 Dec;51(12):961-982. doi: 10.4070/kcj.2021.0995. PMID: 34854578; PMCID: PMC8636761.
  64. Hwang HS, Kim JS, Kim YG, Lee YH, Lee DY, Ahn SY, Moon JY, Lee SH, Ko GJ, Jeong KH. Circulating Neprilysin Level Predicts the Risk of Cardiovascular Events in Hemodialysis Patients. Front Cardiovasc Med. 2021 Jun 15;8:684297. doi: 10.3389/fcvm.2021.684297. PMID: 34212014; PMCID: PMC8239158.
  65. Kim DK, Lee YH, Kim JS, Kim YG, Lee SY, Ahn SY, Lee DY, Jeong KH, Lee SH, Hwang HS, Moon JY. Circulating Vascular Adhesion Protein-1 Level Predicts the Risk of Cardiovascular Events and Mortality in Hemodialysis Patients. Front Cardiovasc Med. 2021 Sep 7;8:701079. doi: 10.3389/fcvm.2021.701079. PMID: 34557529; PMCID: PMC8452851.
  66. Judge P, Haynes R, Landray MJ, Baigent C. Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant. 2015 May;30(5):738-43. doi: 10.1093/ndt/gfu269. Epub 2014 Aug 18. PMID: 25140014; PMCID: PMC4425478.
  67. Judge PK, Haynes R. TaleNeprilysin and Neprilysin inhibition in chronic kidney disease. Curr Opin Nephrol Hypertens. 2021 Jan;30(1):123-130. doi: 10.1097/MNH.0000000000000659. PMID: 33148948.
  68. Solomon SD, Vaduganathan M, L Claggett B, Packer M, Zile M, Swedberg K, Rouleau J, A Pfeffer M, Desai A, Lund LH, Kober L, Anand I, Sweitzer N, Linssen G, Merkely B, Luis Arango J, Vinereanu D, Chen CH, Senni M, Sibulo A, Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJV. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020 Feb 4;141(5):352-361. doi: 10.1161/CIRCULATIONAHA.119.044586. Epub 2019 Nov 17. PMID: 31736342.
  69. Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018 Jul;6(7):547-554. doi: 10.1016/S2213-8587(18)30100-1. Epub 2018 Apr 13. PMID: 29661699.
  70. Jha R, Mukku KK, Rakesh AK, Sinha S. Successful Treatment of Severe Heart Failure in Advanced Diabetic Kidney Disease Using Angiotensin-neprilysin Inhibitors (Sacubitril/Valsartan) - Report of Two Cases with Review of Options in Literature. Indian J Nephrol. 2021 Nov-Dec;31(6):587-591. doi: 10.4103/ijn.IJN_298_20. Epub 2021 Nov 13. PMID: 35068771; PMCID: PMC8722547.
  71. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, Kasiske B, Liu J, Mau LW, McBean M, Murray A, St Peter W, Guo H, Gustafson S, Li Q, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L. US Renal Data System 2010 Annual Data Report. Am J Kidney Dis. 2011 Jan;57(1 Suppl 1):A8, e1-526. doi: 10.1053/j.ajkd.2010.10.007. PMID: 21184928.
  72. Gillen DL, Worcester EM, Coe FL. Decreased renal function among adults with a history of nephrolithiasis: a study of NHANES III. Kidney Int. 2005 Feb;67(2):685-90. doi: 10.1111/j.1523-1755.2005.67128.x. PMID: 15673317.
  73. Uribarri J. Chronic kidney disease and kidney stones. Curr Opin Nephrol Hypertens. 2020 Mar;29(2):237-242. doi: 10.1097/MNH.0000000000000582. PMID: 31972597.
  74. Rule AD, Krambeck AE, Lieske JC. Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol. 2011 Aug;6(8):2069-75. doi: 10.2215/CJN.10651110. Epub 2011 Jul 22. PMID: 21784825; PMCID: PMC3156433.
  75. Gambaro G, Favaro S, D'Angelo A. Risk for renal failure in nephrolithiasis. Am J Kidney Dis. 2001 Feb;37(2):233-43. doi: 10.1053/ajkd.2001.21285. PMID: 11157364.
  76. Hoppe B, Martin-Higueras C. Inherited conditions resulting in nephrolithiasis. Curr Opin Pediatr. 2020 Apr;32(2):273-283. doi: 10.1097/MOP.0000000000000848. PMID: 31789978.
  77. Tran TVM, Maalouf NM. Uric acid stone disease: lessons from recent human physiologic studies. Curr Opin Nephrol Hypertens. 2020 Jul;29(4):407-413. doi: 10.1097/MNH.0000000000000610. PMID: 32398609.
  78. Park S, Lee JP, Kim DK, Kim YS, Lim CS. Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression. PLoS One. 2022 Feb 28;17(2):e0264627. doi: 10.1371/journal.pone.0264627. PMID: 35226683; PMCID: PMC8884483.
  79. Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van't Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712. PMID: 33789010.
  80. Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC; Conference Participants. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015 Jul;88(1):17-27. doi: 10.1038/ki.2015.59. Epub 2015 Mar 18. PMID: 25786098; PMCID: PMC4913350.
  81. Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Bañales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audrézet MP, Ferec C, Le Meur Y, Torres VE; Genkyst Study Group, HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Harris PC. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. Am J Hum Genet. 2016 Jun 2;98(6):1193-1207. doi: 10.1016/j.ajhg.2016.05.004. PMID: 27259053; PMCID: PMC4908191.
  82. Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019 Mar 2;393(10174):919-935. doi: 10.1016/S0140-6736(18)32782-X. Epub 2019 Feb 25. PMID: 30819518.
  83. Kim DY, Park JH. Genetic Mechanisms of ADPKD. Adv Exp Med Biol. 2016;933:13-22. doi: 10.1007/978-981-10-2041-4_2. PMID: 27730431.
  84. Lanktree MB, Chapman AB. New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol. 2017 Dec;13(12):750-768. doi: 10.1038/nrneph.2017.127. Epub 2017 Oct 9. PMID: 28989174.
  85. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018 Mar 1;33(3):477-489. doi: 10.1093/ndt/gfx043. PMID: 28379536; PMCID: PMC6019005.
  86. Bleyer AJ, Kidd K, Živná M, Kmoch S. Autosomal Dominant Tubulointerstitial Kidney Disease. Adv Chronic Kidney Dis. 2017 Mar;24(2):86-93. doi: 10.1053/j.ackd.2016.11.012. PMID: 28284384; PMCID: PMC5488707.
  87. Devuyst O, Olinger E, Weber S, Eckardt KU, Kmoch S, Rampoldi L, Bleyer AJ. Autosomal dominant tubulointerstitial kidney disease. Nat Rev Dis Primers. 2019 Sep 5;5(1):60. doi: 10.1038/s41572-019-0109-9. PMID: 31488840.
  88. Eckardt KU, Alper SL, Antignac C, Bleyer AJ, Chauveau D, Dahan K, Deltas C, Hosking A, Kmoch S, Rampoldi L, Wiesener M, Wolf MT, Devuyst O; Kidney Disease: Improving Global Outcomes. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management--A KDIGO consensus report. Kidney Int. 2015 Oct;88(4):676-83. doi: 10.1038/ki.2015.28. Epub 2015 Mar 4. PMID: 25738250.
  89. Lim MA, Kohli J, Bloom RD. Immunosuppression for kidney transplantation: Where are we now and where are we going? Transplant Rev (Orlando). 2017 Jan;31(1):10-17. doi: 10.1016/j.trre.2016.10.006. Epub 2016 Oct 11. PMID: 28340885.
  90. De Lucena DD, Rangel ÉB. Glucocorticoids use in kidney transplant setting. Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1023-1041. doi: 10.1080/17425255.2018.1530214. Epub 2018 Oct 5. PMID: 30265586.
  91. Clayton PA, McDonald SP, Chapman JR, Chadban SJ. Mycophenolate versus azathioprine for kidney transplantation: a 15-year follow-up of a randomized trial. Transplantation. 2012 Jul 27;94(2):152-8. doi: 10.1097/TP.0b013e31825475a3. PMID: 22728292.
  92. Casey MJ, Meier-Kriesche HU. Calcineurin inhibitors in kidney transplantation: friend or foe? Curr Opin Nephrol Hypertens. 2011 Nov;20(6):610-5. doi: 10.1097/MNH.0b013e32834b4343. PMID: 21885969.
  93. Vanhove T, Annaert P, Kuypers DR. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev. 2016;48(1):88-112. doi: 10.3109/03602532.2016.1151037. Epub 2016 Feb 25. PMID: 26912097.
  94. Fantus D, Rogers NM, Grahammer F, Huber TB, Thomson AW. Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. Nat Rev Nephrol. 2016 Oct;12(10):587-609. doi: 10.1038/nrneph.2016.108. Epub 2016 Aug 1. PMID: 27477490; PMCID: PMC6553645.
  95. Noble J, Jouve T, Janbon B, Rostaing L, Malvezzi P. Belatacept in kidney transplantation and its limitations. Expert Rev Clin Immunol. 2019 Apr;15(4):359-367. doi: 10.1080/1744666X.2019.1574570. Epub 2019 Feb 7. PMID: 30676815.
  96. Wong W, Venetz JP, Tolkoff-Rubin N, Pascual M. 2005 immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors? Transplantation. 2005 Aug 15;80(3):289-96. doi: 10.1097/01.tp.0000168436.76784.45. PMID: 16082321.
  97. Tedesco-Silva H, Del Carmen Rial M, Cruz Santiago J, Mazzali M, Pacheco-Silva A, Torres R. Optimizing the clinical utility of sirolimus-based immunosuppression for kidney transplantation. Clin Transplant. 2019 Feb;33(2):e13464. doi: 10.1111/ctr.13464. Epub 2019 Jan 2. PMID: 30548896.
  98. Préterre J, Visentin J, Saint Cricq M, Kaminski H, Del Bello A, Prezelin-Reydit M, Merville P, Kamar N, Couzi L. Comparison of two strategies based on mammalian target of rapamycin inhibitors in secondary prevention of non-melanoma skin cancer after kidney transplantation, a pilot study. Clin Transplant. 2021 Mar;35(3):e14207. doi: 10.1111/ctr.14207. Epub 2021 Jan 20. PMID: 33369772.
  99. Kuczera P, Ciaston-Mogilska D, Oslizlo B, Hycki A, Wiecek A, Adamczak M. The Prevalence of Metabolic Acidosis in Patients with Different Stages of Chronic Kidney Disease: Single-Centre Study. Kidney Blood Press Res. 2020;45(6):863-872. doi: 10.1159/000508980. Epub 2020 Oct 16. PMID: 33070125.
  100. Di Iorio BR, Bellasi A, Raphael KL, Santoro D, Aucella F, Garofano L, Ceccarelli M, Di Lullo L, Capolongo G, Di Iorio M, Guastaferro P, Capasso G; UBI Study Group. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. J Nephrol. 2019 Dec;32(6):989-1001. doi: 10.1007/s40620-019-00656-5. Epub 2019 Oct 9. Erratum in: J Nephrol. 2020 Jun;33(3):619-620. PMID: 31598912; PMCID: PMC6821658.
  101. Wesson DE, Simoni J. Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet. Kidney Int. 2010 Dec;78(11):1128-35. doi: 10.1038/ki.2010.348. Epub 2010 Sep 22. PMID: 20861823.
  102. Wesson DE, Nathan T, Rose T, Simoni J, Tran RM. Dietary protein induces endothelin-mediated kidney injury through enhanced intrinsic acid production. Kidney Int. 2007 Feb;71(3):210-7. doi: 10.1038/sj.ki.5002036. Epub 2006 Dec 13. PMID: 17164833.
  103. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrol Dial Transplant. 2009 Apr;24(4):1232-7. doi: 10.1093/ndt/gfn633. Epub 2008 Nov 17. PMID: 19015169; PMCID: PMC2721428.
  104. Tangri N, Reaven NL, Funk SE, Ferguson TW, Collister D, Mathur V. Metabolic acidosis is associated with increased risk of adverse kidney outcomes and mortality in patients with non-dialysis dependent chronic kidney disease: an observational cohort study. BMC Nephrol. 2021 May 19;22(1):185. doi: 10.1186/s12882-021-02385-z. PMID: 34011303; PMCID: PMC8136202.
  105. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009 Sep;20(9):2075-84. doi: 10.1681/ASN.2008111205. Epub 2009 Jul 16. PMID: 19608703; PMCID: PMC2736774.
  106. Dobre M, Yang W, Pan Q, Appel L, Bellovich K, Chen J, Feldman H, Fischer MJ, Ham LL, Hostetter T, Jaar BG, Kallem RR, Rosas SE, Scialla JJ, Wolf M, Rahman M; CRIC Study Investigators. Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Heart Assoc. 2015 Apr 20;4(4):e001599. doi: 10.1161/JAHA.114.001599. PMID: 25896890; PMCID: PMC4579944.
  107. Goraya N, Simoni J, Jo CH, Wesson DE. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. Kidney Int. 2014 Nov;86(5):1031-8. doi: 10.1038/ki.2014.83. Epub 2014 Apr 2. PMID: 24694986.
  108. Cupisti A, Kalantar-Zadeh K. Management of natural and added dietary phosphorus burden in kidney disease. Semin Nephrol. 2013 Mar;33(2):180-90. doi: 10.1016/j.semnephrol.2012.12.018. PMID: 23465504; PMCID: PMC5797670.
  109. Alvirdizadeh S, Yuzbashian E, Mirmiran P, Eghtesadi S, Azizi F. A prospective study on total protein, plant protein and animal protein in relation to the risk of incident chronic kidney disease. BMC Nephrol. 2020 Nov 17;21(1):489. doi: 10.1186/s12882-020-02079-y. PMID: 33203389; PMCID: PMC7672990.
  110. Hahn D, Hodson EM, Fouque D. Low protein diets for non-diabetic adults with chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 29;10(10):CD001892. doi: 10.1002/14651858.CD001892.pub5. PMID: 33118160; PMCID: PMC8095031.
  111. Yen CL, Fan PC, Lee CC, Kuo G, Tu KH, Chen JJ, Lee TH, Hsu HH, Tian YC, Chang CH. Advanced Chronic Kidney Disease with Low and Very Low GFR: Can a Low-Protein Diet Supplemented with Ketoanalogues Delay Dialysis? Nutrients. 2020 Oct 31;12(11):3358. doi: 10.3390/nu12113358. PMID: 33142717; PMCID: PMC7694025.
  112. Cupisti A, Licitra R, Chisari C, Stampacchia G, D'Alessandro C, Galetta F, Rossi B, Barsotti G. Skeletal muscle and nutritional assessment in chronic renal failure patients on a protein-restricted diet. J Intern Med. 2004 Jan;255(1):115-24. doi: 10.1046/j.0954-6820.2003.01245.x. PMID: 14687247.
  113. Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol. 2006 Jul;26(4):261-8. doi: 10.1016/j.semnephrol.2006.06.001. PMID: 16949463.
  114. Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol. 2008 Jan;3(1):200-7. doi: 10.2215/CJN.03840907. Epub 2007 Dec 12. PMID: 18077782.
  115. Salamin O, Kuuranne T, Saugy M, Leuenberger N. Erythropoietin as a performance-enhancing drug: Its mechanistic basis, detection, and potential adverse effects. Mol Cell Endocrinol. 2018 Mar 15;464:75-87. doi: 10.1016/j.mce.2017.01.033. Epub 2017 Jan 22. PMID: 28119134.
  116. Pagani A, Nai A, Silvestri L, Camaschella C. Hepcidin and Anemia: A Tight Relationship. Front Physiol. 2019 Oct 9;10:1294. doi: 10.3389/fphys.2019.01294. PMID: 31649559; PMCID: PMC6794341.
  117. Wang CY, Babitt JL. Hepcidin regulation in the anemia of inflammation. Curr Opin Hematol. 2016 May;23(3):189-97. doi: 10.1097/MOH.0000000000000236. PMID: 26886082; PMCID: PMC4993159.
  118. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012 Oct;23(10):1631-4. doi: 10.1681/ASN.2011111078. Epub 2012 Aug 30. PMID: 22935483; PMCID: PMC3458456.
  119. Gupta N, Wish JB. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis. 2017 Jun;69(6):815-826. doi: 10.1053/j.ajkd.2016.12.011. Epub 2017 Feb 24. Erratum in: Am J Kidney Dis. 2017 Jun;69(6):869. PMID: 28242135.
  120. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001 Oct 5;107(1):43-54. doi: 10.1016/s0092-8674(01)00507-4. PMID: 11595184.
  121. Chen N, Qian J, Chen J, Yu X, Mei C, Hao C, Jiang G, Lin H, Zhang X, Zuo L, He Q, Fu P, Li X, Ni D, Hemmerich S, Liu C, Szczech L, Besarab A, Neff TB, Peony Yu KH, Valone FH. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017 Aug 1;32(8):1373-1386. doi: 10.1093/ndt/gfx011. PMID: 28371815; PMCID: PMC5837707.
  122. Colbert GB, Patel D, Lerma EV. Patiromer for the treatment of hyperkalemia. Expert Rev Clin Pharmacol. 2020 Jun;13(6):563-570. doi: 10.1080/17512433.2020.1774363. Epub 2020 Jun 8. PMID: 32511052.
  123. Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Dey J, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 Jun;20(6):1369-1376. doi: 10.1111/dom.13245. Epub 2018 Mar 9. PMID: 29405626; PMCID: PMC5969254.
  124. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007 Sep;2(5):906-13. doi: 10.2215/CJN.01050207. Epub 2007 Aug 16. PMID: 17702727.
  125. Kashtan C. Multidisciplinary Management of Alport Syndrome: Current Perspectives. J Multidiscip Healthc. 2021 May 21;14:1169-1180. doi: 10.2147/JMDH.S284784. PMID: 34045864; PMCID: PMC8149282.
  126. Martinez-Moreno JM, Fontecha-Barriuso M, Martin-Sanchez D, Guerrero-Mauvecin J, Goma-Garces E, Fernandez-Fernandez B, Carriazo S, Sanchez-Niño MD, Ramos AM, Ruiz-Ortega M, Ortiz A, Sanz AB. Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease. Int J Mol Sci. 2020 Jun 9;21(11):4113. doi: 10.3390/ijms21114113. PMID: 32526941; PMCID: PMC7312774.
  127. Kalantar-Zadeh K, Schwartz GG, Nicholls SJ, Buhr KA, Ginsberg HN, Johansson JO, Kulikowski E, Lebioda K, Toth PP, Wong N, Sweeney M, Ray KK; BETonMACE Investigators. Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial. Clin J Am Soc Nephrol. 2021 May 8;16(5):705-716. doi: 10.2215/CJN.16751020. Epub 2021 Apr 27. PMID: 33906908; PMCID: PMC8259488.
  128. Nezu M, Suzuki N, Yamamoto M. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression. Am J Nephrol. 2017;45(6):473-483. doi: 10.1159/000475890. Epub 2017 May 13. PMID: 28502971.
  129. Imig JD. Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. Pharmacol Ther. 2018 Dec;192:1-19. doi: 10.1016/j.pharmthera.2018.06.015. Epub 2018 Jun 30. PMID: 29964123; PMCID: PMC6263841.
  130. Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant. 2011;20(1):5-14. doi: 10.3727/096368910X. PMID: 21396235.
  131. Kuppe C, Kramann R. Role of mesenchymal stem cells in kidney injury and fibrosis. Curr Opin Nephrol Hypertens. 2016 Jul;25(4):372-7. doi: 10.1097/MNH.0000000000000230. PMID: 27191350.
  132. Aghajani Nargesi A, Lerman LO, Eirin A. Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges. Stem Cell Res Ther. 2017 Dec 4;8(1):273. doi: 10.1186/s13287-017-0727-7. PMID: 29202871; PMCID: PMC5713024.
  133. Squillaro T, Peluso G, Galderisi U. Clinical Trials With Mesenchymal Stem Cells: An Update. Cell Transplant. 2016;25(5):829-48. doi: 10.3727/096368915X689622. Epub 2015 Sep 29. PMID: 26423725.
  134. Lee SE, Jang JE, Kim HS, Jung MK, Ko MS, Kim MO, Park HS, Oh W, Choi SJ, Jin HJ, Kim SY, Kim YJ, Kim SW, Kim MK, Sung CO, Pack CG, Lee KU, Koh EH. Mesenchymal stem cells prevent the progression of diabetic nephropathy by improving mitochondrial function in tubular epithelial cells. Exp Mol Med. 2019 Jul 9;51(7):1-14. doi: 10.1038/s12276-019-0268-5. PMID: 31285429; PMCID: PMC6802630.
  135. Yoon YM, Lee JH, Yun CW, Lee SH. Pioglitazone Improves the Function of Human Mesenchymal Stem Cells in Chronic Kidney Disease Patients. Int J Mol Sci. 2019 May 10;20(9):2314. doi: 10.3390/ijms20092314. PMID: 31083336; PMCID: PMC6540009.
  136. Kaur KK, Allahbadia GN, Singh M. An update in the utilization of N-acetylcysteine & vitamin c for tackling the oxidativestress in acute kidney injury secondary to robustsepsis - A systematic review. J Clini Nephrol. 2022; 6: 001-018. DOI: 29328/journal.jcn.1001084.
  137. Kaur KK, Allahbadia GN, Singh M. Potential role of epigenetic modulation in prevention or therapy for Diabetic kidney disease-still a dream or a reality; keynote presentation;2021; at the 3rd Annual Summit on Diabetes, Obesity and Heartheld during December 10, 2021 in Webinar byAllied Academies and the Editors of Journal of Cardiovascular Medicine andTherapeutics. J Cholesterol Heart Disease & J Diabetology.
  138. Kaur KK, Allahbadia GN, Singh M. Can Vitamin D Supplementation prevent / delay/ halt the progression of Diabetic nephropathy; A Systematic Review on mechanism of Vitamin D Crosstalk with Vitamin D Receptor, with others like Megalin-Cubilin and Amnioless Complex along with FGF23-Klotho Complex. J Clin Diabetes Obes 2021.
  139. Kaur KK, Allahbadia GN, Singh M. Optimizing cardiovascular outcome in Type 2 diabetes mellitus with better control of diabetes mellitus with empigliflozin and hypertensionwith renin angiotensin system inhibitors and manidipine preferably of the dihydropyridones. Obes Res Open J. 2020; 7 (1): 13-25. doi: 10.17140/OROJ-7-141.
  140. Kaur KK, Allahbadia GN, Singh M. An update on etiology of Chronic Kidney Disease with role of Associated Vitamin K deficiency in Prevention of Vascular calcification& cardiovascular risks & avoid mortality: A minireview. Acta Scientific Nutritional Health. 2022;6(4).

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Figure 1

Figure 6

Figure 1

Figure 7

Figure 1

Figure 8

Figure 1

Figure 9

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More